In this article, James Matera, DO, writes about a newer agent, finarenone, which is a nonsteroidal, selective mineralocorticoid receptor antagonist that can treat chronic kidney disease.
In this article, James Matera, DO, writes about the new research investigating treatment and management options for patients on dialysis who also develop pruritus.
In this commentary, James Matera, DO, writes about the ESRD treatment choice model that started on January 1, 2021, as well as its importance to and implications for practitioners.
In this Top Papers column, James Matera, DO, writes about 3 important research papers that highlight new potential treatment options for patients with CKD and anemia, and those with CKD and cardiovascular disease.
In this flashback commentary, Dr James Matera from CentraState Medical Center reflects on a case report published in the 1990 issue of Consultant.
In this commentary, Dr James Matera, from CentraState Medical Center, discusses new research on the effects of fruit and vegetable intake on mortality in patients undergoing hemodialysis.
In this commentary, nephrologist James Matera, DO, from CentraState Medical Center in New Jersey, discusses current evidence for the role of dietary modification in slowing CKD and ESRD progression.
In this article, James Matera, DO, FACOI, discusses the results of several recent studies that examined the efficacy and safety of tolvaptan in the management of patients with autosomal dominant polycystic kidney disease, and the potential impact of this treatment option on ESRD development.
In this article, James Matera, DO, talks about the importance of evaluating a patient’s estimated glomerular filtration rate and how an eGFR compares with actual GFR.